法国赛诺菲的喜保宁副作用什么时候消失？

France's Sanofi is an irreversible GABA transaminase inhibitor that can increase the levels of GABA in the brain and cerebrospinal fluid. This drug has been used in Europe since the 1990s to treat infantile spasms [145], and its effect is better than ACTH. In 2009, the U.S. FDA approved the drug for infantile spasms in the United States. Currently, the drug has been listed as a first-line drug treatment for infantile spasms in Europe and North America, and may also have a certain effect on drug-refractory complex partial seizures in TSC patients.

When will the side effects of French Sanofi's Vigabatrin disappear? Patients may experience certain side effects when taking Vigabatrin. The specific time when the side effects disappear varies from person to person. The size of the side effects and the time to subside are also different depending on the patient's physique. It is understood that the side effects of French Sanofi's Vigabatrin include drowsiness, reduced muscle tone, weight gain, insomnia, etc. However, its biggest disadvantage is its impact on visual field. Patients may suffer from irreversible concentric visual field defects. The exact mechanism of this side effect is unknown, but it may be due to decreased function of cones and amacrine cells. This side effect is more common in adult patients than in pediatric patients, with an incidence rate of approximately 25%–50% in adult patients, approximately 15% in pediatric patients, and approximately 15%–31% in infants and young children. The time from the start of treatment to the remission of epilepsy is about 12-35 days. The probability of visual impairment during this period is relatively low. It is currently believed that if there is no obvious effect after more than 12 weeks of use, discontinuation of the drug can be considered.

Recommended related hot articles: /newsDetail/95627.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.